CS08399

(a potential best-in-class brain-penetrant PRMT5-MTA inhibitor) is a methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor that exhibits highly selective antitumor activity against MTAP-deficient tumor cells. CS08399 exerts epigenetic regulation on diverse cell types within the tumor microenvironment through PRMT5 inhibition, demonstrating therapeutic potential in overcoming tumor drug resistance and immune evasion. The company received the Drug Clinical Trial Approval Notice for CS08399 Tablets in March 2026.

CS12088

This is a hepatitis B nucleocapsid assembly modulator exclusively discovered by the company with global patent protection. Preclinical study results demonstrated that CS12088 maintained nanomolar antiviral activity against various genotypes of hepatitis B, exhibiting liver-targeting characteristics and demonstrating favorable safety and tolerability. In February 2025, CS12088 tablets received the clinical trial approval notice.

CS12192

This is a highly selective JAK3 kinase inhibitor exclusively discovered by the company with global patent protection, which also partially inhibits JAK1 and TBK1 kinases; the indication under development is autoimmune diseases. Currently, the company has completed the Phase I clinical trial of CS12192 for rheumatoid arthritis in China.

Leveraging the company's AI-assisted design and integrated chemical genomics technology platform, the R&D pipeline is strategically focused on two major disease areas of neoplasms and metabolism, while continuously monitoring disease areas with significant unmet clinical needs such as neurodegenerative diseases and autoimmune diseases. The company has developed a portfolio of first/best-in-class potential candidates, including CS1011 (for chronic fibrotic diseases), CDCS04 (targeting the Alzheimer's disease genetic risk factor ApoE4 gene), CDCS28 (a non-incretin small molecule for weight loss), and CS1008 (a next-generation multi-target kinase inhibitor simultaneously targeting FLT3 mutations and their resistance-associated pathways). These projects/products are expected to form the core value of the company in the future.